Trumenba

Trumenba. It is a meningococcal vaccine approved for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Developed by Pfizer, it was first approved by the U.S. Food and Drug Administration in 2014 for individuals 10 through 25 years of age. The vaccine addresses a significant cause of meningitis and septicemia, particularly in adolescents and young adults.

Medical uses

Trumenba is indicated for the prevention of invasive meningococcal disease caused by N. meningitidis serogroup B. The Centers for Disease Control and Prevention recommends its use for individuals at increased risk, such as during outbreaks at universities like Princeton University and University of California, Santa Barbara. It is administered as a series of intramuscular injections, with the schedule depending on risk level. The Advisory Committee on Immunization Practices provides guidance on its use alongside other meningococcal vaccines like Menveo and Bexsero.

Adverse effects

Common adverse reactions include pain at injection site, fatigue, headache, myalgia, and chills. These are generally mild to moderate and resolve within a few days. As with all vaccines, there is a rare potential for anaphylaxis or other serious hypersensitivity reactions. Post-marketing surveillance continues to monitor safety, coordinated by agencies like the FDA and the World Health Organization.

Mechanism of action

Trumenba is a recombinant protein vaccine. It contains two lipidated factor H binding protein variants (fHBP) from N. meningitidis that are key for evading the complement system. These antigens induce the production of bactericidal antibodies that target the bacterial capsule and promote opsonophagocytosis. This mechanism helps the immune system neutralize the bacteria, preventing bacteremia and subsequent meningitis.

History

The development of Trumenba was driven by the need for a effective vaccine against meningococcal B strains, following outbreaks in the United States and Europe. Pfizer acquired the technology through its acquisition of Wyeth and Baxter International. It received Breakthrough Therapy designation from the FDA and was approved under the accelerated approval pathway in October 2014. This approval was a significant milestone, as earlier vaccines like Menactra did not cover serogroup B.

Society and culture

The introduction of Trumenba impacted public health policy, particularly for college students living in dormitories. Its use in outbreak responses has been highlighted by the CDC and National Institutes of Health. The vaccine's brand name has become recognized in campaigns by organizations like the Meningitis Research Foundation and the Immunization Action Coalition. Its development is part of broader global efforts against meningococcal disease, involving entities like the World Health Organization and Gavi, the Vaccine Alliance. Category:Vaccines Category:Meningococcal disease